9th Annual Cell Line Development and Engineering Asia – Agenda

Day 1: 3 November 2020

1.00PM
Chairperson’s Opening Remarks


Joint Opening Plenary
Joint Plenary Sessions with 10th Annual Biomanufacturing and 2nd Annual Cell & Gene Therapy Manufacturing


1.10PM
KEYNOTE ADDRESS
China’s Big Leap Towards BioPharma 2030 – Innovation, Industrialization, Internationalization                             

Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

1.40PM
KEYNOTE ADDRESS
China’s Biological Facilities for the Future – WuXi’s Story on Technology and Innovation

Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, China

2.10PM
Online Networking & Stretch Break


9th Annual Cell Line Development & Engineering Asia Commences


 2.20PM
Chairperson’s Opening Remarks

Dr. Orit Aharonovitz, Senior Director, Cell Line & Process Development, Teva Pharmaceuticals, Israel


The State-of-Play for CLD


2.30PM
OPENING KEYNOTE
Optimising Cell Line Development: Applications for Furthering Biopharma R&D Strategy

  • Partnerships and ventures for furthering biopharma R&D capabilities and strategies

Dr. Orit Aharonovitz, Senior Director, Cell Line & Process Development, Teva Pharmaceuticals, Israel

3.00PM
Enhancing Complex Protein Expression with Highly Efficient Gene Integration Technology

Senior Representative from Lonza


Novel Advances in CLD Techniques & Technology


3.30PM
Novel Transposases in Accelerating Cell Line Development

Dr. Claes Gustafsson, Chief Commercial Officer and Co-Founder, ATUM, U.S.

4.00PM
Online Networking & Stretch Break

4.20PM
Efficient Cell Lines and Technology Applications

Lisa Zheng, Executive Director, Cell Line Development, Transcenta, China

4.50PM
Developing a New CLD Process from Ground-Up

  • Navigating the complex landscape of strategies for generating new cell lines
  • From DNA to lead clones, what new technologies and core instrumentation may impact future protein expression and cell line development campaigns?

Mark Stockdale, Amalgamator of Business and Biology, Solentim, U.K.

5.20PM
High-Throughput Cloning Screening and Performance for Next-Generation Innovative Therapeutics

Ting Chen, Director, Alphamab Oncology, China

5.50PM
Expanding Beyond Traditional Monoclonal Antibodies in Cell Line Development

  • Use case for the generation of the highest titer production cell lines in under 1 week
  • A look at how pharma is moving cell line development earlier in the therapeutic development timeline
  • Delivering >99% monoclonality with every campaign through optimizing your CLD workflow

Dr. John Proctor, Senior Vice President, Marketing, Berkeley Lights, U.S.

6.20PM
End of Conference Day 1

Day 2: 4 November 2020

1.00PM
Chairperson’s Opening Remarks


Joint Opening Plenary
Joint Plenary Sessions with 10th Annual Biomanufacturing and 2nd Annual Cell & Gene Therapy Manufacturing


1.10PM
Manufacturers’ Panel:
New Therapies, New Tech and New Investments

  • New frontiers in drug development
  • What is the gap in quality and investment?
  • Embracing new tech and start-ups to drive progress
  • New therapeutics manufacturing, commercialisation and global access
  • Biomanufacturing 4.0 – Where are we at?
  • DAL’s GAMP and licensing laws – How is it affecting our business and what we can expect?
  • The GQCE framework – quality consistency and better pricing

Panelists:
Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals Co., China
Glenn Hassan, Chief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, China
Larry Zhang, President, CASI Pharmaceuticals, China (pending for final confirmation)
Wu Yifang, Chief Executive Officer, Fosun Pharma, China (invited)
James Huang, Executive Chairman & CEO, JHL Biotech, China (invited)
Joe Zhou, Chief Executive Officer, Genor Biopharma, China (invited)

2.00PM
Online Networking & Stretch Break


9th Annual Cell Line Development & Engineering Asia Resumes


2.20PM
Chairperson’s Opening Remarks


Engineering Host Cell Lines, Genomics & CRISPR in Focus


2.30PM
Advances in Glycosylation and Expression Vectors for Recombinant Proteins

Dr. Song Zhiwei, Principal Scientist, Bioprocessing Technology Institute, Singapore

3.00PM
Enabling New Frontiers in Recombinant Protein Therapeutic Development: A Novel and Modular CHO Expression Platform

  • Tackling the pressures on the CHO expression system to express complex proteins – new modules for addressing a range of issues such as translation/secretion bottlenecks, lead candidate selection, quality assessment and barcoding of the clonal production cell line using next generation sequencing
  • Three case studies illustrating the modular approach for the production of a biosimilar, a vaccine and a monoclonal antibody

Dr. Igor Fisch, Chief Executive Officer, Selexis, Switzerland

3.30PM
CRISPR in Cell Line Development:
Applications of CRISPR in Rapid Development of Stable Transgene CHO Cell Lines

Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiaotong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China

4.00PM
Online Networking & Stretch Break

4.20PM
Advances in Single-Cell Genomics and RNA Sequencing Tools for Effective CLD*

Session Reserved for Namocell

4.50PM
Next-Generation Cell Line Engineering for Biopharmaceutical Production

  • Advancing microRNA to optimize and boost productivity of cell line growth
  • Use cases and applications of CRISPR/Cas9-mediated knockout for enhanced titre
  • Identifying bottlenecks in CLD: a streamlined and high-throughput approach

Dr. Kerstin Otte, Professor, Institute of Applied Biotechnology, Biberach University of Applied Sciences, Germany

5.20PM
Applications for Glycan Analysis Workflows and Bioanalytical Proteins*

Senior Representative from ProZyme

5.50PM
Industry Panel: Utilising Platform Technologies for CLD 

  • Navigating the systems and various methods to accomplish their goals; comparing and contrastingtools
  • Case study-focused
  • Dealing with the flow and generation of high-throughput data and information
  • The Biopharma 4.0 paradigm for CLD: digital twins, applications of big data and tech developments for cell culture processes

Panelists:
Dr. Orit Aharonovitz, Senior Director, Cell Line & Process Development, Teva Pharmaceuticals, Israel
Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals, China
Eric Chang, Head, Cell Line Development, JHL Biotech, China
Lisa Zheng, Executive Director, Cell Line Development, Transcenta, China

6.30PM
End of Conference Day 2

Day 3: 5 November 2020

1.00PM
Chairperson’s Opening Remarks


Joint Opening Plenary
Joint Plenary Sessions with 10th Annual Biomanufacturing and 2nd Annual Cell & Gene Therapy Manufacturing


1.10PM
KEYNOTE ADDRESS
China’s Biopharma Capital Markets – Future Funds and Innovative Financing

Fu Wei, Chief Executive Officer, CBC Group, China

1.40PM
Venture Capitals Roundtable:
Show Me the Drug

  • Investment landscape of Chinese biopharma market
  • Evaluating drug pipelines and development prospects
  • Mergers, expansion and JVs – Where do we see transactions picking up?
  • Financing new plants, new therapeutics, product launch and scaling-up operations – How do we review?
  • Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?

Panelists:
Rani Jarkas, Chairman, Cedrus Investments, Hong Kong
Judith Li, Partner, Lilly Asia Ventures, China
Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, China
Lynn Yang, Managing Director, Sequoia Capital, China
Dr. John Zhu, Partner, 6 Dimensions Capital, China

2.20PM
Online Networking & Stretch Break


9th Annual Cell Line Development & Engineering Asia Resumes


2.40PM
Chairperson’s Opening Remarks

Dr. Song Zhiwei, Principal Scientist, Bioprocessing Technology Institute, Singapore


Optimising Workflows and Bioprocesses


2.50PM
High-Throughput and Seamless Workflow Automation in CLD

Dr. Jill Cai, Vice President, Biologics Bioprocess & Development, WuXi Biologics, China

3.20PM
Integrated Cell Line Development Strategy in Whole CMC Picture

  • How to evaluate a CHO based expression systems?
  • Can the cell line generation work be integrated with other process?
  • How to achieve cell lines with high quality and stability under fast workflow?

Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals, China

3.50PM
Accelerating CLD for Commercial Success

Dr. Pan Zhiwei, Senior Director, Process Development, Junshi Pharma, China

4.20PM
Online Networking & Stretch Break

4.40PM
Using CHO to Develop Biosimilars from Non-CHO Host Cell Line

Eric Chang, Head, Cell Line Development, JHL Biotech, China

5.10PM
A Fully Integrated Platform Approach for Highly-Quality CLD

  • Case study in Henlius’ in-house capabilities across the entire biologics value chain spanning across:
    • High-titer cell lines;
    • Proprietary cell culture production; and
    • Continuous manufacturing process for commercial production

Senior Representative from Shanghai Henlius Biotech, China

5.40PM
Panel Discussion: What’s Next in the Future of CLD&E

  • What is the next thing in medicine that we will need to produce?
  • A look ATMPs, tissue generation, stem cells, exosomes and more
  • The landscape for CRISPR: how ready or willing is the industry to use CRISPR for cell line engineering?
  • Partnerships and ventures for furthering biopharma R&D capabilities and strategies

Moderator:
Dr. Song Zhiwei, Principal Scientist, Bioprocessing Technology Institute, Singapore

Panelists:
Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiaotong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China
Dr. Kerstin Otte, Professor, Institute of Applied Biotechnology, Biberach University of Applied Sciences, Germany
Dr. Jill Cai, Vice President, Biologics Bioprocess & Development, WuXi Biologics, China

6.20PM
End of Conference